文献速递乳房整形与再造

重建类型是否重要?倾向性评分分析比较乳房切除术后即刻假体与皮瓣重建

Does the Type of Reconstruction Matter? A Propensity Score Analysis of Immediate Postmastectomy Implant and Flap Reconstruction.
PubMed 文献 · Plast Reconstr Surg · 2023-02-27

本研究基于Weill Cornell乳腺癌登记库1998至2019年行乳房切除术后重建的 retrospective 队列,用倾向性评分匹配比较假体与皮瓣重建的长期肿瘤学结局。匹配前分析假体1395例、皮瓣586例,匹配后各563例,总体生存与复发均无差异。结论认为20年间重建类型与长期肿瘤学结局无关。

要点

  • 匹配前后假体与皮瓣重建的总体生存和复发均无显著差异。
  • 匹配前多因素模型显示医疗保险类型及病理分期、阳性淋巴结数与生存相关。
  • 皮瓣重建10年限制性平均生存时间较假体少2个月,匹配后各5年区间无差异。

核心结论

  • 乳房切除术后重建在20年期间与长期肿瘤学结局差异无关。

研究设计与样本

  • 回顾性研究,使用Weill Cornell乳腺癌登记库1998至2019年乳房切除术后重建患者数据。
  • 以人口学、临床和手术特征为基础进行倾向性评分匹配,匹配前假体1395例、皮瓣586例,匹配后各563例。
  • 采用Kaplan-Meier估计、Cox回归模型和限制性平均生存时间(RMST)评估患者结局。

主要发现

  • 匹配前假体与皮瓣两组总体生存和复发均无差异。
  • 匹配前多因素模型显示医疗保险(Medicare/Medicaid)与生存降低相关(HR 3.09;95%CI 1.63至5.87;P<0.001)。
  • 匹配前多因素模型显示病理II期(HR 2.98;95%CI 1.12至7.90;P=0.028)和III期(HR 4.88;95%CI 1.54至15.5;P=0.007)与生存降低相关。
  • 匹配前多因素模型显示11至20枚淋巴结阳性(HR 3.66;95%CI 1.31至10.2;P=0.013)和超过20枚淋巴结阳性(HR 6.41;95%CI 1.49至27.6;P=0.013)与生存降低相关。
  • 匹配前皮瓣重建10年RMST较假体减少2个月(9.56年 vs 9.74年;95%CI -0.339至-0.024;P=0.024)。

关键数值与推荐

  • 匹配前假体1395例与皮瓣586例比较,总体生存和复发无差异。
  • 匹配后假体563例与皮瓣563例比较,重建类型与总体生存和复发无关。
  • 匹配前皮瓣重建10年RMST为9.56年,假体重建为9.74年,皮瓣较假体减少2个月(95%CI -0.339至-0.024;P=0.024)。
  • 匹配后假体与皮瓣RMST在20年内每个5年区间均无差异。
  • 证据等级:治疗性,III级。

临床怎么用

  • 原文结论认为乳房切除术后重建在20年期间与长期肿瘤学结局差异无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No randomized controlled trials have compared implant and flap reconstruction. Recently, worse longitudinal outcomes have been suggested for flap reconstruction. The authors compared long-term oncologic outcomes of postmastectomy breast reconstruction using propensity score matching. METHODS: A retrospective study of postmastectomy reconstruction was achieved using the Weill Cornell Breast Cancer Registry between 1998 and 2019. Patients were matched using propensity scores based on demographic, clinical, and surgical characteristics. Kaplan-Meier estimates, Cox-regression models, and restricted mean survival times (RMST) were used to evaluate patient outcomes. RESULTS: Before matching, 1395 implant and 586 flap patients were analyzed. No difference in overall survival and recurrence were observed. Multivariable models showed decreased survival for Medicare/Medicaid [hazard ratio (HR), 3.09; 95% CI, 1.63 to 5.87; P < 0.001], pathologic stage II (HR, 2.98; 95% CI, 1.12 to 7.90; P = 0.028), stage III (HR, 4.88; 95% CI, 1.54 to 15.5; P = 0.007), 11 to 20 lymph nodes positive (HR, 3.66; 95% CI, 1.31 to 10.2; P = 0.013), more than 20 lymph nodes positive (HR, 6.41; 95% CI, 1.49 to 27.6; P = 0.013). RMST at 10 years after flap reconstruction showed 2 months of decreased survival time compared with implants (9.56 versus 9.74 years; 95% CI, -0.339 to -0.024; P = 0.024). After matching, 563 implant and 563 flap patients were compared. Reconstruction was not associated with overall survival and recurrence. RMST between implant and flap reconstruction showed no difference in each 5-year interval over 20 years. CONCLUSION: Postmastectomy breast reconstruction was not associated with a difference in long-term oncologic outcomes over a 20-year period. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Jung WF, Pollie MP, Ho KK, et al. Does the Type of Reconstruction Matter? A Propensity Score Analysis of Immediate Postmastectomy Implant and Flap Reconstruction. Plast Reconstr Surg. 2023. PMID: 36827476. doi:10.1097/PRS.0000000000010319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。